CASE REPORT article
Front. Oncol.
Sec. Cancer Immunity and Immunotherapy
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1621494
This article is part of the Research TopicCancer Therapy Related Organ ToxicitiesView all 10 articles
Successful rescue of PD-1 inhibitor-induced TEN by vincristine combination therapy: a case report and literature review
Provisionally accepted
- Department of Oncology, Guangzhou Chest Hospital, Guangzhou, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
With the growing use of immune checkpoint inhibitors (ICIs) in the management of various solid malignancies, immune-related adverse events (irAEs) are increasingly recognized. Toxic epidermal necrolysis (TEN), though rare, represents a severe and potentially fatal cutaneous irAE with a high mortality rate. Owing to its low incidence and limited clinical data, a standardized treatment approach for ICI-induced TEN has not been established. We present a patient who developed TEN following the administration of a programmed cell death-1 inhibitor. The patient was successfully managed with a combination of vincristine, intravenous immunoglobulin, and glucocorticoids at the Department of Oncology, Guangzhou Chest Hospital.
Keywords: Vincristine (VCR), Toxic epidermal necrolysis (TEN), Immune-related adverse events (IRAE), PD-1 inhibitor, Immune check point inhibitor (ICI)
Received: 01 May 2025; Accepted: 20 Aug 2025.
Copyright: © 2025 Huang, Liu, Zeng, Huang and Su. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Shan Su, Department of Oncology, Guangzhou Chest Hospital, Guangzhou, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.